# US 2013/0158007 A1 · Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158007 A1
- Document ID: US20130158007A1
- Status: Published application
- Kind: A1
- Application number: 13/770,462
- Filed: 2013-02-19
- Published: 2013-06-20
- Earliest claimed: 2010-03-11
- Assignees: KemPharm, Inc.
- Inventors: Travis Mickle; Sven Guenther; Sanjib Bera
- Web page: https://patentgrep.com/patent/US20130158007A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D 285/36: Seven-membered rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.

## Claims

### Claim 1

A composition for treating a psychiatric disorder in a subject, comprising a prodrug conjugate of 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine) and a straight chain, saturated fatty acid having the general formula of CnH2n+1—CO2H, wherein n is 1-7.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the prodrug conjugate has the following structure:

### Claim 3 (depends on 1)

The composition of claim 1, wherein n is 1.

### Claim 4 (depends on 1)

The composition of claim 1, wherein n is 4.

### Claim 5 (depends on 1)

The composition of claim 1, wherein n is 7.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the straight chain, saturated fatty acid is acetate or ethanoate.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the prodrug conjugate has the following structure:

### Claim 8 (depends on 1)

The composition of claim 1, wherein the straight chain, saturated fatty acid is valerate or pentanoate.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the prodrug conjugate has the following structure:

### Claim 10 (depends on 1)

The composition of claim 1, wherein the straight chain, saturated fatty acid is caprylate or octanoate.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the prodrug conjugate has the following structure:

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition has a higher relative bioavailability than non-conjugated quetiapine when administered orally.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the prodrug conjugate is in a salt form selected from the group consisting of acetate, L-aspartate, besylate, bicarbonate, carbonate, D-camsylate, L-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, D-lactate, L-lactate, D,L-lactate, D,L-malate, L-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, D-tartrate, L-tartrate, D,L-tartrate, meso-tartrate, benzoate, gluceptate, D-glucuronate, hybenzate, isethionate, malonate, methylsufate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate; and a mixture thereof.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition is formulated for oral, sublingual, transdermal, suppository, or intrathecal administration.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the composition formulated for oral administration is a tablet, capsule, caplet, pill, powder, troche, lozenge, slurry, liquid solution, suspension, emulsion, elixir or oral thin film (OTF).

### Claim 16 (depends on 1)

The composition of claim 1, wherein the prodrug conjugate is present in an amount per unit dose of between about 1 mg and about 2000 mg per unit dose of the composition.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the prodrug conjugate is present in an amount per unit dose of between about 150 mg and about 800 mg per unit dose of the composition.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the amount per unit dose is based on the amount of quetiapine present in the prodrug conjugate; or wherein the amount per unit dose is based on the amount of quetiapine in a salt of the prodrug conjugate.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the psychiatric disorder is at least one of schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, restless legs syndrome, autism, alcoholism, depression, insomnia, Tourette syndrome or a combination thereof.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the subject is a human or a mammal subject.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the subject has not been diagnosed with schizophrenia or bipolar disorder.

### Claim 22 (depends on 1)

The composition of claim 1, further comprising one or more of: lithium, divalproex, adjuvants, antiadherents, binders, coatings, disintegrants, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents, sweeteners or a combination thereof.

### Claim 23 (depends on 1)

The composition of claim 1 wherein the composition is a combination of the prodrug conjugate and a salt of the prodrug conjugate.
